Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3786
Peer-review started: May 7, 2018
First decision: May 16, 2018
Revised: June 30, 2018
Accepted: July 16, 2018
Article in press: July 16, 2018
Published online: September 7, 2018
Processing time: 122 Days and 22.5 Hours
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant epithelial cancer originating from bile ducts with cholangiocyte differentiation. In recent years, chronic cirrhosis and viral hepatitis have been recognized as important risk factors for ICC development. ICC has been increasingly found in patients with cirrhosis, and distinguishing between ICC and hepatocellular carcinoma (HCC) is a major clinical issue because the management and prognosis of these conditions differ significantly.
The contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS®) sets the specific category of LR-M for distinguishing ICC from HCC, but the diagnostic dilemma remains unresolved. Additionally, no study has validated the performance of LR-M as the differential diagnostic criterion for ICC and HCC.
To identify important imaging predictors of ICC on CEUS, to develop a novel diagnostic nomogram incorporating clinical, CEUS and laboratory characteristics that could be used to accurately predict the risk of ICC in high-risk patients and to compare the nomogram with modified CEUS LI-RADS.
This retrospective study consisted of 88 consecutive high-risk patients with ICC and 88 high-risk patients with HCC selected by propensity score matching between May 2004 and July 2016. Patients were assigned to two groups, namely, a training set and validation set, at a 1:1 ratio. A CEUS score for diagnosing ICC was generated based on significant CEUS features. Then, a nomogram based on the CEUS score was developed, integrating the clinical data. The performance of the nomogram was then validated and compared with that of the LR-M of the CEUS LI-RADS.
The most useful CEUS features for ICC were as follows: rim enhancement (64.5%), early washout (91.9%), intratumoral vein (58.1%), obscure boundary of intratumoral non-enhanced area (64.5%), and marked washout (61.3%, all P < 0.05). In the validation set, the area under the curve (AUC) of the CEUS score (AUC = 0.953) for differentiation between ICC and HCC were improved compared to the LI-RADS (AUC = 0.742) (P < 0.001). When clinical data were added, the CEUS score nomogram was superior to the LI-RADS nomogram (AUC: 0.973 vs 0.916, P = 0.036, NRI: 0.077, IDI: 0.152). Subgroup analysis demonstrated that the CEUS score model was notably improved compared to the LI-RADS in under 5.0 cm tumors (P < 0.05) but not improved in tumors under 3.0 cm (P > 0.05).
A CEUS score for predicting ICC consisted of more detailed CEUS features (rim enhancement, early washout, intratumoral vein, obscure boundary of intratumoral non-enhanced area, and marked washout) was constructed.
The diagnostic performance of the CEUS score (AUC = 0.953) for differentiation between ICC and HCC was improved compared to the LR-M of LI-RADS (AUC = 0.742) (P < 0.001). A CEUS score nomogram that added the clinical risk factors was superior to the LI-RADS nomogram (AUC: 0.973 vs 0.916, P = 0.036, NRI: 0.077, IDI: 0.152). The CEUS score predictive model was notably improved compared to the LI-RADS in ≤ 5.0 cm tumors (P < 0.05) but not improved in tumors ≤ 3.0 cm (P > 0.05).
The CEUS predictive model for differentiation between ICC and HCC in high-risk patients had improved discrimination and clinical usefulness compared to the CEUS LI-RADS.